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Abstract This short version of the interdisciplinary S3
guideline on hormone therapy in peri- and postmenopause
(HT) is intended as a decision-making instrument for
physicians and women considering HT. It is designed to
assist daily practice. This short version summarises the
long version that contains detailed information about the
development of the guideline, particularly about estab-
lishing the evidence levels. The statements and recom-
mendations, quoted completely, are marked with the
relevant levels of evidence (LoE) and grades of recom-
mendation. The classiﬁcation system from the Centre for
Evidence-based Medicine in Oxford was used in this
guideline (see ‘‘Attachment’’).
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Abbreviations
HT Hormone therapy in the perimenopause and
postmenopause
ET Estrogen therapy
EPT Estrogen–progestin therapy
LoE Level of evidence
WHI Women’s Health Initiative
HERS Heart and Estrogen/Progestin Replacement
Study
VTE Venous thromboembolism
CPA Cyproterone acetate
CMA Chlormadinon acetate
DNG Dienogest
DRSP Drospirenone
WHIMS The Women’s Health Initiative Memory
Study
CEE Conjugated equine estrogens
MPA Medroxyprogesterone acetate
SSRI Selective serotonine reuptake inhibitor
Introduction
Peri- and post-menopausal women often seek medical
assistance because of climacteric symptoms (e.g. hot ﬂu-
shes and sweating), considering HT for the treatment of
these symptoms. They hope for alleviation of these
symptoms and possibly an improvement in their quality of
life. While ageing, the symptoms may change, and there
may be dysfunctions or diseases that also depend on sex
hormones. This situation can inﬂuence the assessment of
the risk–beneﬁt ratio. The prevention of diseases that fre-
quently develop in postmenopausal women is also often an
issue when discussing HT.
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There are clinically relevant differences between the
available estrogens, progestins and estrogen-progestin
combinations as well as between the various forms of
application of HT. These differences apply to the beneﬁt as
well as to some risks, and they should be taken into account
when managing individual cases.
Climacteric symptoms and their treatment
During the climacteric period, women often suffer from
vasomotor complaints (hot ﬂushes) and vaginal dryness.
These symptoms were the most consistent ﬁndings
observed in studies in this period of life. Other problems
such as disturbed sleep, various physical symptoms, pain,
urinary tract disorders, sexual problems and mood ﬂuctua-
tions have a less consistent association with the menopausal
transition period. Estrogens are the most effective treatment
for hot ﬂushes and vaginal atrophy. The frequency of these
complaints can be markedly reduced by HT, or the symp-
toms will even disappear completely. There are other
complaints associated with the climacteric period which
may be relieved with HT. If HT is indicated, an improve-
ment of the woman’s general well-being is possible.
Statements
Hot ﬂushes and vaginal dryness are associated with the
transition from premenopause to postmenopause; the fre-
quency of reports on these symptoms varies (LoE 2a).
Other complaints like disturbed sleep, various physical
symptoms, urinary tract disorders, sexual problems, or
mood ﬂuctuations are inconsistently reported symptoms
(LoE 2a).
Degree of consensus: strong consensus
Estrogens are effective for the treatment of hot ﬂushes
(LoE 1a)
Conjugated equine estrogens, oral 17b-estradiol, and
transdermal 17b-estradiol reduce hot ﬂushes to a compa-
rable degree (LoE 1a).
An additional treatment with progestins does not interfere
withtheeffectofestrogensonvasomotorcomplaints(LoE1a).
Tibolone is effective in the treatment of hot ﬂushes
(LoE 1a).
There is no difference in the effect of estrogen therapy
on hot ﬂushes between women with natural menopause and
women after bilateral oophorectomy (LoE 1a).
(see also the chapter on urogenital symptoms).
Degree of consensus: strong consensus
In women who were treated with various estrogens or
estrogen-progestin combinations, positive as well as
negative effects on the quality of life were found, but in
some instances no effect was noted (LoE 1a).
Degree of consensus: consensus
Recommendations
When assessing the risk–beneﬁt ratio, one should bear in
mind that the only two complaints most consistently
reported by women during the menopausal transition are
hot ﬂushes and vaginal dryness (A).
Degree of consensus: consensus
Hot ﬂushes can be treated with estrogens or, if applicable,
estrogen-progestin combinations, or with tibolone (A).
When deciding on the indication, the risks and beneﬁts
presented in this guideline should be taken into account (A).
Degree of consensus: strong consensus
The sole improvement of a woman’s so-called general
well-being or health-related quality of life is not an indi-
cation for HT (B).
Degree of consensus: strong consensus
Vulvovaginal atrophy
Systemic HT or local estrogen therapy (ET) prevents or
reverses vaginal atrophy. Low-dose local ET is as effective
as systemic treatment. Local ET is signiﬁcantly more
effective than placebo or local therapy without hormones.
Statement
HT is effective for preventing and/or treating vaginal
atrophy (LoE 1a).
Degree of consensus: strong consensus
Recommendation
If symptomatic vaginal atrophy is the only indication for
therapy, local vaginal ET should be recommended (A).
Degree of consensus: consensus
Urinary incontinence
Earlier studies reported that ET can improve or even cure
urinary incontinence, especially urge incontinence.
Including data from the Women’s Health Initiative (WHI)
study and the Heart and Estrogen/progestin Replacement
Study (HERS), more recent systematic reviews concluded
that oral HT increases the risk for urinary incontinence or
may lead to a deterioration of existing incontinence.
Transdermal or vaginal estrogen application resulted in
inconclusive improvement of incontinence. The efﬁcacy of
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been proven. Local ET is often used as an adjunct com-
bined with i.e. surgical therapies.
Statement
Oral HT has a negative inﬂuence on urinary incontinence
(LoE 1a).
A clear positive effect of local and transdermal therapies
could not be demonstrated (LoE 1a).
Degree of consensus: consensus
Recommendation
Oral HT should not be recommended for the treatment of
urinary incontinence (B).
Degree of consensus: consensus
Statement
There are other medications and therapeutic measures with
proven efﬁcacy for the treatment of urinary incontinence
that should be recommended (LoE 1a).
Degree of consensus: consensus
Recurrent urinary tract infection
Studies with oral HT did not show any effect on the inci-
dence of urinary tract infections. In some smaller studies
and studies with heterogeneous methodologies, vaginal
estrogen treatment led to a signiﬁcant reduction of urinary
tract infections.
Statement
Oral HT is not appropriate for the prevention of recurrent
urinary tract infections (LoE 1a).
Vaginal estrogen therapy is effective (LoE 2a).
Degree of consensus: strong consensus
Recommendation
Vaginal estrogen treatment can be recommended for
recurrent urinary tract infections (B).
Degree of consensus: strong consensus
Locomotor system and bone metabolism
A reduction of the incidence of bone fractures by HT was
shown in a large number of studies. HT reduced the rate of
clinical fractures as well as the rate of osteoporosis-
associated fractures. Even low doses (0.3 mg of conjugated
estrogens, 0.5 mg of oral 17-b-estradiol or 14 lgo f
transdermal 17-b-estradiol) have been shown to reduce the
loss of bone mass; a reduction in fracture rates has not been
proven conclusively with these doses. HT is effective in the
primary prevention of osteoporosis and osteoporosis-asso-
ciated fractures.
Statement
HT signiﬁcantly reduces the incidence of fractures
(LoE 1a).
Degree of consensus: strong consensus
Recommendation
After consideration of risks and beneﬁts, HT can be used
for the prevention of fractures, for those women at high
risk, if the woman cannot tolerate other ﬁrst-line drugs
recommended for the treatment of osteoporosis or if these
drugs are contraindicated (A).
Degree of consensus: consensus
Coronary heart disease
HT is not indicated for the primary or secondary pre-
vention of coronary heart disease in women at any age
because there are other strategies with proven efﬁcacy.
However, numerous ﬁndings from observational studies
suggest that HT may reduce the risk of myocardial
infarction, when started early. In contrast to these ﬁnd-
ings, the WHI study, a randomized controlled trial, found
a non-signiﬁcant trend of risk reduction by ET in women
aged 50–59 years, but not in older women. With com-
bined estrogen–progestin therapy (EPT), the risk was
increased at the beginning of treatment, but not after
treatment duration of 5.6 years. Particularly, older women
and women with a predisposition for cardiovascular dis-
ease had an increased risk at the beginning of treatment.
Especially in older women ([60 years), systemic HT
should only be initiated after careful assessment of risks
and beneﬁts, taking any pre-existing risk factors into
consideration.
Recommendation
HT is not indicated for the primary or secondary prevention
of coronary heart disease (B).
There are other strategies with proven efﬁcacy for pri-
mary or secondary prevention (A).
Degree of consensus: strong consensus
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HTincreasestheriskforanischaemiccerebrovascularevent.
This risk should always be considered in the assessment of
risks and beneﬁts, particularly in older women.
Statement
HT increases the risk for an ischaemic cerebrovascular
event (LoE 1a).
Degree of consensus: strong consensus
Recommendation
The increased risk of stroke must always be considered in
the assessment of risks and beneﬁts of HT (A).
Degree of consensus: strong consensus
Thromboembolic disease
HT increases the risk of venous thrombosis and pulmonary
embolism, particularly in the ﬁrst year of use and in the
presence of risk factors such as congenital coagulation
disorders. A meta-analysis of observational studies shows
that the risk is lower with transdermal HT.
Statement
Oral HT increases the risk of venous thrombosis and pul-
monary embolism (VTE) (LoE 1a).
Degree of consensus: strong consensus
Recommendation
The increased risk of VTE must be considered while
assessing the risks and beneﬁts of HT. The risk is partic-
ularly high in the ﬁrst year of HT use and further increases
if there are additional predisposing risk factors for venous
thrombosis (A).
Degree of consensus: strong consensus
Skin ageing
Available data are insufﬁcient to make reliable statements
on the effects of HT on the processes of skin ageing.
Smaller comparative studies have, in part, shown a positive
effect of estrogens on parameters of skin ageing. The
limited number of randomized studies with small numbers
of cases and signiﬁcant methodological ﬂaws, respectively
have not yielded any reliable results.
Statement
An alleviation of skin ageing processes by HT has not been
proven (LoE 2b).
Degree of consensus: strong consensus
Recommendation
HT is not indicated for alleviating the processes of skin
ageing (A).
Degree of consensus: strong consensus
Signs of skin androgenisation
There is only a small number of evaluable trials using HT
with anti-androgenic progestins (cyproterone acetate
[CPA], chlormadinone acetate [CMA], dienogest [DNG],
and drospirenone [DRSP]) in the climacteric period. In
particular, it is impossible to state if HT with anti-andro-
genic progestins can result in a signiﬁcant improvement of
androgenic skin changes, because there have been no
speciﬁc trials addressing this question. However, if a
combined estrogen–progestin therapy is indicated, women
with cutaneous signs of androgenisation should primarily
receive preparations with an anti-androgenic progestin
compound instead of a preparation with a progestin
deriving from the 19-nortestosterone group.
Statement
Alleviation of the signs of skin androgenisation with HT
has not been proven (LoE 5).
Degree of consensus: strong consensus
Recommendation
HT is not indicated to alleviate signs of skin androgeni-
sation (A).
Degree of consensus: strong consensus
Diseases of the gall bladder and gall ducts
HT increases the risk of gall duct disease. This is mainly
the effect of the estrogen compound. The risk is probably
less profound with transdermal estrogen application.
Statement
There is evidence that diseases of the gall bladder and
gall ducts, particularly cholecystolithiasis, cholecystitis/
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quently with HT (LoE Ib).
Degree of consensus: strong consensus
Recommendation
When assessing the risks and beneﬁts of HT, the increased
risk of cholecystitis/cholangitis, cholecystolithiasis and
cholecystectomies must be taken into account (A).
Degree of consensus: consensus
Cognition
There is limited evidence from older clinical trials that ET
has a short-term positive effect on cognition when used in
premenopausal women after bilateral oophorectomy. The
long-term effects of HT started during the menopausal
transition or during the early postmenopausal period are
unknown. Neither ET nor EPT were able to prevent the
decline of cognitive functions in older postmenopausal
women, either as short- or long-term treatment. The evi-
dence is insufﬁcient to assess if special forms of HT may
confer any beneﬁt.
Statement
HT does not have a positive effect on cognition in older
postmenopausal women (LoE 2a).
Degree of consensus: strong consensus
Recommendation
HT should not be recommended to alleviate impairments of
cognition in postmenopausal women (B).
Degree of consensus: strong consensus
Dementia
Observational studies have demonstrated a reduction of the
risk for dementia, e.g. Alzheimer’s disease, with the use of
HT. However, these studies are heterogeneous and show a
substantial bias. Therefore, based on the insufﬁcient quality
of the data, it is not possible to make recommendations on
the basis of available evidence.
In the Women’s Health Initiative Memory Study
(WHIMS), the relationship between HT and dementia in
women over 65 years was investigated as part of the WHI.
The endpoint ‘‘mild cognitive impairment’’ did not show
any difference between HT and placebo, either with con-
jugated equine estrogens (CEE) plus medroxyprogesterone
acetate (MPA), or with CEE alone. With the endpoint
‘‘possible dementia’’, there was a signiﬁcantly increased
relative risk for the combination of CEE and MPA, but not
for CEE alone, versus placebo.
In women with a diagnosis from mild to moderate
Alzheimer’s dementia, there was no signiﬁcant difference
between 1-year ET and placebo as to the overall appear-
ance of the Alzheimer’s dementia.
Statements
HT does not show any beneﬁt on the signs of dementia in
women with Alzheimer’s disease (LoE 1a).
Degree of consensus: strong consensus
Continuous combined HT increases the risk of dementia
in women aged over 65 years (LoE 2a).
Degree of consensus: strong consensus
Recommendation
HT should not be recommended to decrease the risk of
dementia (A).
Degree of consensus: strong consensus
Breast cancer
The use of HT increases the risk of breast cancer. The
increased risk was seen after duration of use of 5 or more
years. Meta-analyses incorporating both observational
studies and randomized controlled trials have also shown
an increased risk of breast cancer with ET alone. The effect
was weaker than with EPT. In addition, the increase of risk
by ET, compared with EPT, was only seen after a longer
duration of use. The WHI did not show any increased
risk after a mean duration of ET use of 7.1 years. After HT
is discontinued, the risk decreases. After a few years, the
risk does not differ from the risk of women who never used
HT.
Statements
EPT increases the risk of breast cancer (LoE 1b).
ET increases the risk of breast cancer to a lesser degree
than EPT (LoE 2a).
Degree of consensus: strong consensus/consensus
Recommendation
The increased risk of breast cancer must be considered
while assessing the beneﬁts and risks of HT (A).
Degree of consensus: strong consensus
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ET leads to an increased risk of endometrial cancer. The
effect is dependent on the duration of use and on the
estrogen dose. EPT combined with a progestin, applied at
an adequate dosage for at least 10 days per treatment
month, does not increase the risk of endometrial cancer.
Low-dose vaginal ET, as used to prevent vaginal atro-
phy, probably does not increase the risk of endometrial
cancer. However, data on this issue are very limited.
Statement
ET increases the risk of endometrial cancer, whereas
combined EPT with at least ten; better twelve days of
progestin application per treatment month does not.
(LoE 1a).
Degree of consensus: strong consensus
Recommendation
ET should only be used in hysterectomized women.
Combined EPT in non-hysterectomized women should
include a progestin application for at least 10 days, better
12 days per treatment month (A).
Degree of consensus: strong consensus
Ovarian cancer
In the past, the relation between HT use and the risk of
ovarian cancer was discussed controversially. Recent meta-
analyses have shown an increased risk for ovarian cancer
with the use of ET or EPT.
Statement
HT increases the risk of ovarian cancer. It is unclear if
there are any differences between ET and EPT (LoE 2a).
Degree of consensus: strong consensus
Recommendation
The increased risk of ovarian cancer must be considered
while assessing the risks and beneﬁts of HT (A).
Degree of consensus: strong consensus
Colorectal cancer
According to observational studies, the risk of colorectal
cancer is reduced in women who have used ET or EPT.
The risk reduction was more pronounced in current users of
HT. In the WHI, a randomized, placebo-controlled trial,
only EPT led to a signiﬁcant risk reduction.
Statement
EPT decreases the risk of colorectal cancer; ET does not
(LoE 2a).
Degree of consensus: consensus
Recommendation
This does not result in an indication for HT (A).
Degree of consensus: strong consensus
HT in cancer patients
According to a recent randomized trial, HT use after breast
cancer leads to a markedly increased risk of recurrence.
Assessing the risk of HT after endometrial, ovarian or
colorectal cancer is difﬁcult because only few observa-
tional studies are available. These did not demonstrate an
increased risk of recurrence when HT was used. Yet, the
number of cases is too low to draw reliable conclusions
about the safety of HT after treatment of the cancer entities
mentioned earlier.
Statements
HT increases the risk of recurrence when used after breast
cancer (LoE 2b).
The risk of HT use after treated endometrial, ovarian
or colorectal cancer has not been studied sufﬁciently
(LoE 2b).
Since lack of data, no statement is possible regarding
other types of tumours (LoE 5).
Degree of consensus: strong consensus/consensus
Recommendation
HT is contraindicated after breast cancer treatment (A).
Degree of consensus: strong consensus
Premature menopause
Women with premature menopause (\40 years of age)
are a heterogeneous group. The available studies have
mostly investigated women with surgical oophorectomy.
From a clinical point of view, it seems to make sense to
use HT in women with premature menopause, at least
until the average age of natural menopause (about
50 years).
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It is unclear whether the beneﬁts and risks of HT in women
with premature menopause differ from those in women
with natural menopause aged around 50 years (LoE 2a).
HT is appropriate for the treatment of hot ﬂushes and
vaginal atrophy in symptomatic women with premature
menopause (LoE 2a).
Degree of consensus: strong consensus/consensus
Recommendation
In women with premature menopause, HT can be used until
the average age of natural menopause (0).
Degree of consensus: consensus
Alternative therapies
Currently, there is no evidence that herbal remedies have a
reliable effect on vasomotor complaints. Isoﬂavones or
Cimicifuga racemosa can be considered in cases of mild hot
ﬂushes or sweating, since a decrease of climacteric com-
plaints is possible in few cases. It is not possible to predict if
thistreatmentwillbeeffectiveintheindividualcase.Incases
of severe vasomotor complaints, a sufﬁcient therapeutic
effect cannot be expected. If there are contraindications
against hormonal therapies, and the woman expresses an
urgent desire for treatment, selective serotonin re-uptake
inhibitors (SSRI) and gabapentin may be considered as an
individual experimental treatment. It should be noted that
neither medication is currently approved for this indication.
Therefore, a medical justiﬁcation based on the risk–beneﬁt
assessment is needed, and the patient must be thoroughly
informed about the situation (‘‘off label use’’). For all alter-
native therapies, there is a lack of data on long-term safety.
Statements
Isoﬂavone containing supplements made from soybeans
or red clover, or a nutrition rich in phytoestrogens, do
not reduce hot ﬂushes, or only marginally, if at all
(LoE 1a).
Currently, the possible risks of alternative therapies
cannot be assessed with sufﬁcient reliability (LoE 1a).
Degree of consensus: strong consensus
Recommendation
Phytoestrogens and other herbal or non-hormonal therapies
cannot be recommended as an alternative to HT (0).
Degree of consensus: strong consensus
Risk communication
Risk communication is deﬁned as communication about
the probabilities of expected beneﬁts and the possible risks
of harm by HT, with the patient and possibly with an
accompanying person.
For an individual assessment and evaluation of the
probability of beneﬁt and the risk of harm, individual
factors such as the woman’s general state of health, age,
age at menopause, previous HT, duration of use, dosage
and type of HT, and diseases while using HT should be
taken into consideration. In order to give adequate infor-
mation about the risks to the woman seeking advice, the
doctor must be familiar with the principles of risk calcu-
lation. He or she should also be able to communicate the
probabilities in such a way that the patient can make her
own individual decision for or against the initiation of HT.
The ﬁgures necessary for this communication can be found
in the long version and in the balance sheet (see
‘‘attachments’’).
Attachment
Levels of evidence
Oxford Centre for Evidence-based Medicine Levels of
Evidence. (March 2009) (for deﬁnitions of terms used see
glossary at http://www.cebm.net/?o=1116).
Level Therapy/
prevention,
aetiology/harm
Prognosis Diagnosis Differential
diagnosis/symptom
prevalence study
Economic and
decision analyses
1a SR (with
homogeneity*)
of RCTs
SR (with homogeneity*) of
inception cohort studies; CDR

validated in different
populations
SR (with homogeneity*) of Level 1
diagnostic studies; CDR
 with 1b
studies from different clinical centres
SR (with
homogeneity*) of
prospective
cohort studies
SR (with
homogeneity*) of
Level 1 economic
studies
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Level Therapy/
prevention,
aetiology/harm
Prognosis Diagnosis Differential
diagnosis/
symptom
prevalence study
Economic and decision analyses
1b Individual RCT
(with narrow
conﬁdence
interval
)
Individual inception cohort
study with[80% follow-up;
CDR
 validated in a single
population
Validating** cohort study
with good
 reference
standards; or CDR
 tested
within one clinical centre
Prospective
cohort study
with good
follow-up****
Analysis based on clinically
sensible costs or alternatives;
systematic review(s) of the
evidence; and including multi-
way sensitivity analyses
1c All or none
§ All or none case-series Absolute SpPins and
SnNouts

All or none case-
series
Absolute better-value or worse-
value analyses

2a SR (with
homogeneity*)
of cohort
studies
SR (with homogeneity*) of
either retrospective cohort
studies or untreated control
groups in RCTs
SR (with homogeneity*) of
Level[2 diagnostic studies
SR (with
homogeneity*)
of 2b and better
studies
SR (with homogeneity*) of
Level[2 economic studies
2b Individual cohort
study
(including low
quality RCT;
e.g.\80%
follow-up)
Retrospective cohort study or
follow-up of untreated control
patients in an RCT;
Derivation of CDR
 or
validated on split-sample
§§§
only
Exploratory** cohort study
with good
 reference
standards; CDR
 after
derivation, or validated only
on split-sample
§§§ or
databases
Retrospective
cohort study, or
poor follow-up
Analysis based on clinically
sensible costs or alternatives;
limited review(s) of the
evidence, or single studies;
and including multi-way
sensitivity analyses
2c ‘‘Outcomes’’
research;
ecological
studies
‘‘Outcomes’’ research Ecological
studies
Audit or outcomes research
3a SR (with
homogeneity*)
of case–control
studies
SR (with homogeneity*) of 3b
and better studies
SR (with
homogeneity*)
of 3b and better
studies
SR (with homogeneity*) of 3b
and better studies
3b Individual case–
control study
Non-consecutive study; or
without consistently applied
reference standards
Non-consecutive
cohort study, or
very limited
population
Analysis based on limited
alternatives or costs, poor
quality estimates of data, but
including sensitivity analyses
incorporating clinically
sensible variations
4 Case-series (and
poor quality
cohort and
case–control
studies
§§)
Case-series (and poor quality
prognostic cohort studies***)
Case–control study, poor or
non-independent reference
standard
Case-series or
superseded
reference
standards
Analysis with no sensitivity
analysis
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Level Therapy/prevention,
aetiology/harm
Prognosis Diagnosis Differential diagnosis/
symptom prevalence study
Economic and decision
analyses
5 Expert opinion without
explicit critical
appraisal, or based on
physiology, bench
research or ‘‘ﬁrst
principles’’
Expert opinion without
explicit critical
appraisal, or based on
physiology, bench
research or ‘‘ﬁrst
principles’’
Expert opinion without
explicit critical
appraisal, or based on
physiology, bench
research or ‘‘ﬁrst
principles’’
Expert opinion without
explicit critical
appraisal, or based on
physiology, bench
research or ‘‘ﬁrst
principles’’
Expert opinion without
explicit critical
appraisal, or based on
economic theory or
‘‘ﬁrst principles’’
Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998.
Updated by Jeremy Howick March 2009
Notes: Users can add a minus-sign ‘‘-’’ to denote the level of that fails to provide a conclusive answer because: either a single result with a wide
conﬁdence interval or a systematic review with troublesome heterogeneity. Such evidence is inconclusive, and therefore can only generate Grade
D recommendations
* By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of results
between individual studies. Not all systematic reviews with statistically signiﬁcant heterogeneity need be worrisome, and not all worrisome
heterogeneity need be statistically signiﬁcant. As noted above, studies displaying worrisome heterogeneity should be tagged with a ‘‘-’’ at the
end of their designated level
 Clinical Decision Rule. (These are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category.)
 See note above for advice on how to understand, rate and use trials or other studies with wide conﬁdence intervals
§ Met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx became
available, but none now die on it
§§ By poor quality cohort study we mean one that failed to clearly deﬁne comparison groups and/or failed to measure exposures and outcomes
in the same (preferably blinded), objective way in both exposed and non-exposed individuals and/or failed to identify or appropriately control
known confounders and/or failed to carry out a sufﬁciently long and complete follow-up of patients. By poor quality case–control study we mean
one that failed to clearly deﬁne comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective
way in both cases and controls and/or failed to identify or appropriately control known confounders
§§§ Split-sample validation is achieved by collecting all the information in a single tranche, then artiﬁcially dividing this into ‘‘derivation’’ and
‘‘validation’’ samples
 An ‘‘Absolute SpPin’’ is a diagnostic ﬁnding whose speciﬁcity is so high that a positive result rules-in the diagnosis. An ‘‘Absolute SnNout’’
is a diagnostic ﬁnding whose sensitivity is so high that a negative result rules-out the diagnosis
 Good, better, bad and worse refer to the comparisons between treatments in terms of their clinical risks and beneﬁts
 Good reference standards are independent of the test, and applied blindly or objectively to applied to all patients. Poor reference standards
are haphazardly applied, but still independent of the test. Use of a non-independent reference standard (where the ‘test’ is included in the
‘reference’, or where the ‘testing’ affects the ‘reference’) implies a level 4 study
 Better-value treatments are clearly as good but cheaper, or better at the same or reduced cost. Worse-value treatments are as good and more
expensive, or worse and the equally or more expensive
** Validating studies test the quality of a speciﬁc diagnostic test, based on prior evidence. An exploratory study collects information and trawls
the data (e.g. using a regression analysis) to ﬁnd which factors are ‘signiﬁcant’
*** By poor quality prognostic cohort study we mean one in which sampling was biased in favour of patients who already had the target
outcome, or the measurement of outcomes was accomplished in\80% of study patients, or outcomes were determined in an unblinded, non-
objective way, or there was no correction for confounding factors
**** Good follow-up in a differential diagnosis study is[80%, with adequate time for alternative diagnoses to emerge (for example 1–6 months
acute, 1–5 years chronic)
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Balance sheet
A Consistent level 1 studies
B Consistent level 2 or 3 studies or extrapolations from level 1 studies
C Level 4 studies or extrapolations from level 2 or 3 studies
D Level 5 evidence or troublingly inconsistent or inconclusive studies of any level
‘‘Extrapolations’’ are where data is used in a situation that has potentially clinically important differences than the original study situation
Consensus criteria for the degree of recommendation:
Consistency of trial results
Clinical relevance of endpoints and potency of effect
Risk–beneﬁt ratio
Ethical commitment
Patient preference
Feasibility, practicability
Degree Degree of recommendation for the option for action according to (2)
A Strong recommendation ‘shall’
B Recommendation ‘should’
0 Recommendation open ‘can’ (option for action)
Negative recommendations are expressed by using the word ‘not’ with the same symbols
GA Guideline adaptation
GCP Good clinical practice
GEP Good epidemiology practice
Table
Endpoint (EPT) Relative risks (RR) ET: estrogen
therapy, EPT: estrogen-
progestin therapy
Absolute risks (AR) Number needed to harm
(?NNH)/number needed to
treat (-NNT)
Hot ﬂushes OR 0.13 (95% CI 0.07–0.23) n/a n/a
Recurrent urinary
tract infections
Vaginal ET (2 studies): n/a n/a
RR 0.25 (95% CI 0.13–0.30)
RR 0.64 (95% CI 0.47–0.86)
Coronary heart
disease
ET: myocardial infarction and
coronary death: HR 0.91 (95%
CI 0.75–1.12)
-5 events/10,000 women/year of use (corresponding to 49
events [hormone group] versus 54 events [placebo group];
statistically not signiﬁcant)
After myocardial infarction: HR
0.99 (95% CI 0.70–1.41)
EPT: HR 1.24 (95% CI
1.00–1.54)
?6 events/10,000 women/year of use (39 events [hormone
group] versus 33 events [placebo group])
?1,667
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stration of the risk of HT with respect to different
endpoints.
There are different indices available to quantify the
effect of interventions:
Absolute risk reduction (ARR) describes the absolute
difference in the rate of undesirable events in the experi-
mental group (E) compared with the control group (C) if
the experimental treatment is effective (ARR = C - E).
Table continued
Endpoint (EPT) Relative risks (RR) ET: estrogen
therapy, EPT: estrogen-
progestin therapy
Absolute risks (AR) Number needed to harm
(?NNH)/number needed to
treat (-NNT)
Stroke ET: cerebrovascular accident:
HR 1.39 (95% CI 1.10–1.77)
?12 events/10,000 women/year of use (44 events [hormone
group] versus 32 events [placebo group])
?833
EPT: ischaemic stroke: HR:
1.44 (95% CI 1.09–1.90)
?8 events/10,000 women/year of use (26 events [hormone
group] versus 18 events [placebo group])
?1,250
Haemorrhagic stroke: HR 0.82
(95% CI 0.43–1.56)
?0 events/10,000 women/year of use (4 events [hormone
group] versus 4 events [placebo group])
Thromboembolic
events
ET: HR 1.47 (95% CI adjusted
0.87–2.47)
?6 events/10,000 women/year of use (21 events [hormone
group] versus 15 events [placebo group])
?1,667
EPT: HR 2.06 (95% CI adjusted
1.57–2.70)
?17 events/10,000 women/year of use (35 events [hormone
group] versus 17 events [placebo group])
?588
Dementia EPT: RR 1.97 (95% CI
1.16–3.33)
?23 events/10,000 women/year of use (45 events [hormone
group] versus 22 events [placebo group])
?435
Fractures EPT: femoral neck fractures:
HR 0.66 (95% CI 0.45–0.98)
-5 events/10,000 women/year of use (10 fractures
[hormone group] versus 15 fractures [placebo group])
–2,000
Vertebral body fractures: HR
0.66 (95% CI 0.44–0.98)
-6 events/10,000 women/year of use (9 fractures [hormone
group] versus 15 fractures [placebo group])
–1,667
Total rate of fractures: HR 0.76
(95% CI 0.69–0.85)
-44 events/10,000 women/year of use (147 fractures
[hormone group] versus 191 fractures [placebo group])
–227
ET: fractures of the proximal
femur: HR 0.61 (95% CI
0.41–0.91)
-6 events/10,000 women/year of use (11 fractures
[hormone group] versus 17 fractures [placebo group])
–1,667
Vertebral body fractures: HR
0.62 (95% CI 0.42–0.93)
-6 events/10,000 women/year of use (11 [hormone group]
versus 17 fractures [placebo group])
-1,667
Total rate of fractures: HR 0.70
(95% CI 0.63–0.79)
-56 events/10,000 women/year of use (139 fractures
[hormone group] versus 195 fractures [placebo group])
-179
Gall duct disease
(any)
ET: HR 1.67 (95% CI
1.35–2.06)
?31 events/10,000 women/year of use (78 events [hormone
group] versus 47 events [placebo group])
?323
EPT: HR 1.59 (95% CI
1.28–1.97)
?20 events/10,000 women/year of use (55 [hormone group]
versus 35 events [placebo group])
?500
Breast cancer EPT: RR 1.26 (95% CI
1.00–1.59)
?8 breast cancers/10,000 women/year of use (38 events
[hormone group] versus 30 events [placebo group])
?1,250
ET: RR 0.77 (95% CI
0.59–1.01)
-7 breast cancers/10,000 women/year of use (statistically
non-signiﬁcant)
Ovarian cancer EPT: RR 1.11 (95% CI
1.020–1.207)
ET: RR 1.284 (95% CI
1.178–1.399)
Colorectal cancer EPT: HR 0.63 (95% CI
0.43–0.92)
-6 colorectal carcinomas/10,000 women/year of use (10
events [hormone group] versus 16 events [placebo group])
-1,667
ET: HR 1.08 (95% CI
0.75–1.55)
?1 colorectal carcinoma/ 10,000 women/year of use
(statistically non-signiﬁcant)
After breast
cancer
EPT: HR 2.4 (95% CI 1.3–4.2)
For references, see the chapter ‘‘Risk Communication’’ in the long version
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to treat (1/ARR = NNT). NNT is a clinically intuitive
measure for endpoints to describe the effects of a certain
treatment. It represents the number of patients who must be
treated to prevent one additional undesirable event.
The absolute risk increase (ARI) describes the absolute
difference in the rate of undesirable events in the experi-
mental group in comparison with the control group if the
experimental treatment is worse (ARI = |C - E|).
The reciprocal value of the ARI is the number needed to
harm (NNH). NNH is a clinically intuitive measure for
endpoints to describe the unwanted effects of a certain
treatment. It represents the number of patients who must be
treated to cause one additional undesirable event.
The relative risk reduction (RRR) describes the relative
decrease in the rate of undesirable events in the experi-
mental study group as compared with the control group
(RRR = |C - E|/C).
Example: Phlebothrombosis
If the yearly rate of phlebothrombosis in postmeno-
pausal users of oral ET is 22 in 10,000 women, and the rate
in non-users is 11 in 10,000 women, the RR is
RR ¼
22
10;000=year
 
11
10;000=year
¼ 2
This means a doubled risk of phlebothrombosis when
using ET for 1 year. An RR of more than 1.0 indicates an
increased risk. An RR of 1.2 signiﬁes a risk increase by
20%. An RR of less than 1.0 indicates a decrease of risk.
An RR of 0.5, for example, would mean a risk decrease by
50%—the probability of an event when using ET would
then be only half as high as with non-use.
For the evaluation of risks, it is often more useful to
state the absolute risk (AR). The AR describes the risk
difference by calculating the difference in the incidence
between exposed and non-exposed populations. In the
example used above (phlebothrombosis in ET users) the
AR is
AR ¼
22
10;000=year
 
11
10;000=year
¼
11
10;000=year
This means that there will be 11 additional
phlebothromboses per year for every 10,000 women
using oral ET. Changes in the AR are, however,
signiﬁcantly inﬂuenced by the pre-existing risk found in
the exposed persons.
Report on guidelines and methods
The long version, the list of references and the detailed
report on guidelines and methods are published in German
on the DGGG homepage (http://www.dggg.de, area
‘‘Leitlinien’’).
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